Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies

Bhagwatwar, 1996, Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy, Cancer Chemother Pharmacol, 37, 401, 10.1007/s002800050404 Santos, 1983, Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide, N Engl J Med, 309, 1347, 10.1056/NEJM198312013092202 Tutschka, 1987, Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen, Blood, 70, 1382, 10.1182/blood.V70.5.1382.1382 Andersson, 2002, Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study, Biol Blood Marrow Transplant, 8, 145, 10.1053/bbmt.2002.v8.pm11939604 Andersson, 2000, Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study, Biol Blood Marrow Transplant, 6, 548, 10.1016/S1083-8791(00)70064-4 de Lima, 2004, Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS, Blood, 104, 857, 10.1182/blood-2004-02-0414 Madden, 2007, Pharmacokinetics of once-daily intravenous busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule, Biol Blood Marrow Transplant, 13, 56, 10.1016/j.bbmt.2006.08.037 Russell, 2002, Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes, Biol Blood Marrow Transplant, 8, 468, 10.1053/bbmt.2002.v8.pm12374451 Andersson, 2008, Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS, Biol Blood Marrow Transplant, 14, 672, 10.1016/j.bbmt.2008.03.009 Bartelink, 2014, Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity, Biol Blood Marrow Transplant, 20, 345, 10.1016/j.bbmt.2013.11.027 Chae, 2007, New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2, Bone Marrow Transplant, 40, 541, 10.1038/sj.bmt.1705770 Bredeson, 2008, Outcomes following HSCT using fludarabine, busulfan and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide, Biol Blood Marrow Transplant, 14, 993, 10.1016/j.bbmt.2008.06.009 Lee, 2013, Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine, J Clin Oncol, 31, 701, 10.1200/JCO.2011.40.2362 Liu, 2013, Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study, Int J Hematol, 98, 708, 10.1007/s12185-013-1460-3 Rambaldi, 2015, Busulfan plus cycophosphamide versus bulsulfan plus fludarabine as a perparative regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia: an open-label, multicentre, ransomised, phase 3 trial, Lancet Oncol, 15, 1525, 10.1016/S1470-2045(15)00200-4 Bredeson, 2013, Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation, Blood, 122, 3871, 10.1182/blood-2013-08-519009 Pasquini, 2013, 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders, Clin Transpl, 187 Bacigalupo, 2009, Defining the intensity of conditioning regimens: working definitions, Biol Blood Marrow Transplant, 15, 1628, 10.1016/j.bbmt.2009.07.004 Giralt, 2009, Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research, Biol Blood Marrow Transplant, 15, 367, 10.1016/j.bbmt.2008.12.497 Klein, 2003 Copelan, 1992, Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation, Blood, 80, 1648, 10.1182/blood.V80.7.1648.1648 Grochow, 1989, Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother Pharmacol, 25, 55, 10.1007/BF00694339 Hassan, 1994, Busulfan bioavailability, Blood, 84, 2144, 10.1182/blood.V84.7.2144.2144 McDonald, 1993, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, 118, 255, 10.7326/0003-4819-118-4-199302150-00003 Slattery, 1997, Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation, Blood, 89, 3055, 10.1182/blood.V89.8.3055 Sato, 2015, Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation, Int J Hematol, 101, 497, 10.1007/s12185-015-1756-6 Clemmons, 2015, Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?, J Oncol Pharm Pract, 21, 425, 10.1177/1078155214541571 Gandhi, 2002, Cellular and clinical pharmacology of fludarabine, Clin Pharmacokinet, 41, 93, 10.2165/00003088-200241020-00002 Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756 Bornhauser, 2003, Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells, Blood, 102, 820, 10.1182/blood-2002-11-3567 Perkins, 2012, Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 18, 1099, 10.1016/j.bbmt.2011.12.584 Mohty, 2015, Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial, Cancer, 121, 562, 10.1002/cncr.29087 Russell, 2013, Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation, Biol Blood Marrow Transplant, 19, 1381, 10.1016/j.bbmt.2013.07.002 Hassan, 2013, Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation, Pharmacogenomics, 14, 75, 10.2217/pgs.12.185